Product Description
3-Amino-1-propanesulfonic acid is regarded as a promising therapeutic candidate for Alzheimer’s disease (AD). It is presently in Phase III clinical trials throughout North America and Europe, with corresponding trial findings already published. This compound can bind to soluble Aβ peptides, which in turn mitigates the aggregation, deposition and buildup of amyloid proteins within the brain.
Chemical Properties
| Melting point | 293 °C (dec.)(lit.) |
| Density | 1.202 (estimate) |
| Refractive index | 1.5130 (estimate) |
| Storage temp | 2-8°C |
| Solubility | Water (Slightly) |
| Pka | 1.06±0.50(Predicted) |
| Form | Crystalline Powder |
| Color | White to slightly blue |
| LogP | -4.555 |
| CAS DataBase Reference | 3687-18-1(CAS DataBase Reference) |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| WGK Germany | 1 |
| HS Code | 29049090 |
Product Application
The metabolic pathway of 3-aminopropanesulfonic acid is critical to its pharmacokinetic profile and therapeutic efficacy. To boost its therapeutic performance and systemic bioavailability—for instance, by improving chemical stability or slowing metabolic degradation—developing prodrugs and derivatives of this compound represents a viable approach. Following administration, these modified analogs release 3-aminopropanesulfonic acid inside the body, which further enhances its clinical application potential.
